Clinical Characteristics and Survival of Patients With De Novo Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy and Taxane-based Chemotherapy in Uganda: a Retrospective Cohort Study Article Swipe
Alex Bakenga
,
Barbra Natukunda
,
Fred Okuku
,
Kelvin Roland Mubiru
,
Edward Kakungulu
,
Eddy Kyagulanyi
,
Jackson Orem
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-5036307/v1
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-5036307/v1
Background: Prostate cancer is the second most common cancer among men worldwide. Mortality is highest among patients in resource-limited settings, in part due to late-stage disease. Among patients with metastatic prostate cancer (mPCa), studies have shown significant improvement in overall survival with the use of androgen deprivation therapy (ADT) and taxane-based chemotherapy. However, outcome data among patients treated with chemo-endocrine therapy are scarce in many resource-limited settings (RLSs). The aim of this study was to determine the clinical characteristics and 5-year overall survival (OS) of patients with de novo mPCa treated at the Uganda Cancer Institute (UCI). Methods: A retrospective cohort study was conducted between 2015 and 2019, and the data of patients with histologically confirmed prostate cancer and radiological evidence of metastasis were reviewed. Data on clinical and laboratory characteristics, overall survival, and predictors of survival were extracted. P<0.05 was considered to indicate statistical significance. Results: A total of 300 patients were enrolled over the 5-year study period. The median age was 68 (IQR 61.5-74) years. At presentation, lower urinary tract symptoms were reported in nearly all patients (96.7%, n=290), and 40% (n=120) of patients had grade 5 histological scores. In addition to receiving ADT, the majority of patients (70.3%, n=211) received at least 6 cycles of chemotherapy. Overall survival at one year was 92.4% (95% CI: 88.6%-94.9%), but it declined to 45.2% (95% CI: 36.8%-53.2%) at 5 years. A high Gleason score, the presence of visceral metastasis and receiving Conclusion: Patients with de novo mPCa in Uganda present with high histologic grades and high baseline PSA levels but have improved 5-year overall survival with a combination of chemotherapy and ADT as a first-line treatment. We recommend interventions to reduce late presentation and prospective studies to evaluate treatment efficacy in this population.
Related Topics
Concepts
Taxane
Medicine
Prostate cancer
Oncology
Retrospective cohort study
Androgen deprivation therapy
Chemotherapy
Internal medicine
Cohort
Overall survival
Prostate
Cancer
Gynecology
Breast cancer
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.21203/rs.3.rs-5036307/v1
- https://www.researchsquare.com/article/rs-5036307/latest.pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4403650833
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4403650833Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-5036307/v1Digital Object Identifier
- Title
-
Clinical Characteristics and Survival of Patients With De Novo Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy and Taxane-based Chemotherapy in Uganda: a Retrospective Cohort StudyWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-10-22Full publication date if available
- Authors
-
Alex Bakenga, Barbra Natukunda, Fred Okuku, Kelvin Roland Mubiru, Edward Kakungulu, Eddy Kyagulanyi, Jackson OremList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-5036307/v1Publisher landing page
- PDF URL
-
https://www.researchsquare.com/article/rs-5036307/latest.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.researchsquare.com/article/rs-5036307/latest.pdfDirect OA link when available
- Concepts
-
Taxane, Medicine, Prostate cancer, Oncology, Retrospective cohort study, Androgen deprivation therapy, Chemotherapy, Internal medicine, Cohort, Overall survival, Prostate, Cancer, Gynecology, Breast cancerTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4403650833 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-5036307/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-5036307/v1 |
| ids.openalex | https://openalex.org/W4403650833 |
| fwci | 0.0 |
| type | preprint |
| title | Clinical Characteristics and Survival of Patients With De Novo Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy and Taxane-based Chemotherapy in Uganda: a Retrospective Cohort Study |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10543 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9984999895095825 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Prostate Cancer Treatment and Research |
| topics[1].id | https://openalex.org/T12708 |
| topics[1].field.id | https://openalex.org/fields/20 |
| topics[1].field.display_name | Economics, Econometrics and Finance |
| topics[1].score | 0.949400007724762 |
| topics[1].domain.id | https://openalex.org/domains/2 |
| topics[1].domain.display_name | Social Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2002 |
| topics[1].subfield.display_name | Economics and Econometrics |
| topics[1].display_name | Economic and Financial Impacts of Cancer |
| topics[2].id | https://openalex.org/T10124 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9447000026702881 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2740 |
| topics[2].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[2].display_name | Prostate Cancer Diagnosis and Treatment |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777511904 |
| concepts[0].level | 4 |
| concepts[0].score | 0.8705670833587646 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q425227 |
| concepts[0].display_name | Taxane |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7318027019500732 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2780192828 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7221676111221313 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q181257 |
| concepts[2].display_name | Prostate cancer |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.7033644318580627 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C167135981 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6783400774002075 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2146302 |
| concepts[4].display_name | Retrospective cohort study |
| concepts[5].id | https://openalex.org/C2777899217 |
| concepts[5].level | 4 |
| concepts[5].score | 0.656793475151062 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q4759439 |
| concepts[5].display_name | Androgen deprivation therapy |
| concepts[6].id | https://openalex.org/C2776694085 |
| concepts[6].level | 2 |
| concepts[6].score | 0.6519815921783447 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[6].display_name | Chemotherapy |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.5494144558906555 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C72563966 |
| concepts[8].level | 2 |
| concepts[8].score | 0.5259678363800049 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[8].display_name | Cohort |
| concepts[9].id | https://openalex.org/C3019894029 |
| concepts[9].level | 2 |
| concepts[9].score | 0.43844422698020935 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q332823 |
| concepts[9].display_name | Overall survival |
| concepts[10].id | https://openalex.org/C2776235491 |
| concepts[10].level | 3 |
| concepts[10].score | 0.41768568754196167 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q9625 |
| concepts[10].display_name | Prostate |
| concepts[11].id | https://openalex.org/C121608353 |
| concepts[11].level | 2 |
| concepts[11].score | 0.3966849446296692 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[11].display_name | Cancer |
| concepts[12].id | https://openalex.org/C29456083 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3906617760658264 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1221899 |
| concepts[12].display_name | Gynecology |
| concepts[13].id | https://openalex.org/C530470458 |
| concepts[13].level | 3 |
| concepts[13].score | 0.13854220509529114 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[13].display_name | Breast cancer |
| keywords[0].id | https://openalex.org/keywords/taxane |
| keywords[0].score | 0.8705670833587646 |
| keywords[0].display_name | Taxane |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7318027019500732 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/prostate-cancer |
| keywords[2].score | 0.7221676111221313 |
| keywords[2].display_name | Prostate cancer |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.7033644318580627 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/retrospective-cohort-study |
| keywords[4].score | 0.6783400774002075 |
| keywords[4].display_name | Retrospective cohort study |
| keywords[5].id | https://openalex.org/keywords/androgen-deprivation-therapy |
| keywords[5].score | 0.656793475151062 |
| keywords[5].display_name | Androgen deprivation therapy |
| keywords[6].id | https://openalex.org/keywords/chemotherapy |
| keywords[6].score | 0.6519815921783447 |
| keywords[6].display_name | Chemotherapy |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.5494144558906555 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/cohort |
| keywords[8].score | 0.5259678363800049 |
| keywords[8].display_name | Cohort |
| keywords[9].id | https://openalex.org/keywords/overall-survival |
| keywords[9].score | 0.43844422698020935 |
| keywords[9].display_name | Overall survival |
| keywords[10].id | https://openalex.org/keywords/prostate |
| keywords[10].score | 0.41768568754196167 |
| keywords[10].display_name | Prostate |
| keywords[11].id | https://openalex.org/keywords/cancer |
| keywords[11].score | 0.3966849446296692 |
| keywords[11].display_name | Cancer |
| keywords[12].id | https://openalex.org/keywords/gynecology |
| keywords[12].score | 0.3906617760658264 |
| keywords[12].display_name | Gynecology |
| keywords[13].id | https://openalex.org/keywords/breast-cancer |
| keywords[13].score | 0.13854220509529114 |
| keywords[13].display_name | Breast cancer |
| language | en |
| locations[0].id | doi:10.21203/rs.3.rs-5036307/v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.researchsquare.com/article/rs-5036307/latest.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-5036307/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5064013803 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Alex Bakenga |
| authorships[0].countries | UG |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210117779 |
| authorships[0].affiliations[0].raw_affiliation_string | Uganda Cancer Institute |
| authorships[0].institutions[0].id | https://openalex.org/I4210117779 |
| authorships[0].institutions[0].ror | https://ror.org/02e6sh902 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I2800872281, https://openalex.org/I4210117779, https://openalex.org/I72227227 |
| authorships[0].institutions[0].country_code | UG |
| authorships[0].institutions[0].display_name | Uganda Cancer Institute |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Alex Bakenga |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Uganda Cancer Institute |
| authorships[1].author.id | https://openalex.org/A5060775835 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-4006-0580 |
| authorships[1].author.display_name | Barbra Natukunda |
| authorships[1].countries | UG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210117779 |
| authorships[1].affiliations[0].raw_affiliation_string | Uganda Cancer Institute |
| authorships[1].institutions[0].id | https://openalex.org/I4210117779 |
| authorships[1].institutions[0].ror | https://ror.org/02e6sh902 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I2800872281, https://openalex.org/I4210117779, https://openalex.org/I72227227 |
| authorships[1].institutions[0].country_code | UG |
| authorships[1].institutions[0].display_name | Uganda Cancer Institute |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Barbra Natukunda |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Uganda Cancer Institute |
| authorships[2].author.id | https://openalex.org/A5110246080 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Fred Okuku |
| authorships[2].countries | UG |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210117779 |
| authorships[2].affiliations[0].raw_affiliation_string | Uganda Cancer Institute |
| authorships[2].institutions[0].id | https://openalex.org/I4210117779 |
| authorships[2].institutions[0].ror | https://ror.org/02e6sh902 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I2800872281, https://openalex.org/I4210117779, https://openalex.org/I72227227 |
| authorships[2].institutions[0].country_code | UG |
| authorships[2].institutions[0].display_name | Uganda Cancer Institute |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Fred Okuku¹ |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Uganda Cancer Institute |
| authorships[3].author.id | https://openalex.org/A5060342316 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-8647-2399 |
| authorships[3].author.display_name | Kelvin Roland Mubiru |
| authorships[3].countries | US, ZA |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1326427960, https://openalex.org/I4210127473 |
| authorships[3].affiliations[0].raw_affiliation_string | Hutchinson Cancer Research Center |
| authorships[3].institutions[0].id | https://openalex.org/I4210127473 |
| authorships[3].institutions[0].ror | https://ror.org/03fbwjm33 |
| authorships[3].institutions[0].type | nonprofit |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210127473 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Cancer Research Center |
| authorships[3].institutions[1].id | https://openalex.org/I1326427960 |
| authorships[3].institutions[1].ror | https://ror.org/00wdsp051 |
| authorships[3].institutions[1].type | nonprofit |
| authorships[3].institutions[1].lineage | https://openalex.org/I1326427960, https://openalex.org/I4210089486 |
| authorships[3].institutions[1].country_code | ZA |
| authorships[3].institutions[1].display_name | Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Kelvin Roland Mubiru |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Hutchinson Cancer Research Center |
| authorships[4].author.id | https://openalex.org/A5000581365 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-6212-1006 |
| authorships[4].author.display_name | Edward Kakungulu |
| authorships[4].countries | UG |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210117779 |
| authorships[4].affiliations[0].raw_affiliation_string | Uganda Cancer Institute |
| authorships[4].institutions[0].id | https://openalex.org/I4210117779 |
| authorships[4].institutions[0].ror | https://ror.org/02e6sh902 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I2800872281, https://openalex.org/I4210117779, https://openalex.org/I72227227 |
| authorships[4].institutions[0].country_code | UG |
| authorships[4].institutions[0].display_name | Uganda Cancer Institute |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Edward Kakungulu |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Uganda Cancer Institute |
| authorships[5].author.id | https://openalex.org/A5077863747 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Eddy Kyagulanyi |
| authorships[5].countries | UG |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[5].affiliations[0].raw_affiliation_string | Makerere University |
| authorships[5].institutions[0].id | https://openalex.org/I72227227 |
| authorships[5].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[5].institutions[0].country_code | UG |
| authorships[5].institutions[0].display_name | Makerere University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Eddy Kyagulanyi |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Makerere University |
| authorships[6].author.id | https://openalex.org/A5102929002 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Jackson Orem |
| authorships[6].countries | UG |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210117779 |
| authorships[6].affiliations[0].raw_affiliation_string | Uganda Cancer Institute |
| authorships[6].institutions[0].id | https://openalex.org/I4210117779 |
| authorships[6].institutions[0].ror | https://ror.org/02e6sh902 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I2800872281, https://openalex.org/I4210117779, https://openalex.org/I72227227 |
| authorships[6].institutions[0].country_code | UG |
| authorships[6].institutions[0].display_name | Uganda Cancer Institute |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Jackson Orem¹ |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Uganda Cancer Institute |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.researchsquare.com/article/rs-5036307/latest.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Clinical Characteristics and Survival of Patients With De Novo Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy and Taxane-based Chemotherapy in Uganda: a Retrospective Cohort Study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10543 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9984999895095825 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Prostate Cancer Treatment and Research |
| related_works | https://openalex.org/W2728894889, https://openalex.org/W2753537866, https://openalex.org/W2033949587, https://openalex.org/W2035098213, https://openalex.org/W4200552296, https://openalex.org/W4223420209, https://openalex.org/W4292811293, https://openalex.org/W2960491491, https://openalex.org/W2896276799, https://openalex.org/W1963763301 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-5036307/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.researchsquare.com/article/rs-5036307/latest.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-5036307/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-5036307/v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.researchsquare.com/article/rs-5036307/latest.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-5036307/v1 |
| publication_date | 2024-10-22 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.5 | 189, 229 |
| abstract_inverted_index.6 | 206 |
| abstract_inverted_index.A | 99, 231 |
| abstract_inverted_index.a | 276, 283 |
| abstract_inverted_index.68 | 164 |
| abstract_inverted_index.At | 168 |
| abstract_inverted_index.In | 192 |
| abstract_inverted_index.We | 286 |
| abstract_inverted_index.as | 282 |
| abstract_inverted_index.at | 92, 204, 212, 228 |
| abstract_inverted_index.de | 88, 254 |
| abstract_inverted_index.in | 18, 21, 39, 64, 176, 257, 300 |
| abstract_inverted_index.is | 4, 14 |
| abstract_inverted_index.it | 221 |
| abstract_inverted_index.of | 45, 71, 85, 112, 122, 136, 150, 185, 199, 208, 237, 244, 248, 278 |
| abstract_inverted_index.on | 127 |
| abstract_inverted_index.to | 24, 75, 143, 194, 223, 289, 296 |
| abstract_inverted_index.300 | 151 |
| abstract_inverted_index.40% | 183 |
| abstract_inverted_index.ADT | 281 |
| abstract_inverted_index.CI: | 218, 226 |
| abstract_inverted_index.PSA | 267 |
| abstract_inverted_index.The | 69, 160 |
| abstract_inverted_index.age | 162 |
| abstract_inverted_index.aim | 70 |
| abstract_inverted_index.all | 178 |
| abstract_inverted_index.and | 50, 80, 107, 109, 119, 129, 134, 182, 240, 264, 280, 293 |
| abstract_inverted_index.are | 62 |
| abstract_inverted_index.but | 220, 269 |
| abstract_inverted_index.due | 23 |
| abstract_inverted_index.had | 187 |
| abstract_inverted_index.men | 11 |
| abstract_inverted_index.one | 213 |
| abstract_inverted_index.the | 5, 43, 77, 93, 110, 156, 197, 235 |
| abstract_inverted_index.use | 44 |
| abstract_inverted_index.was | 74, 103, 141, 163, 215 |
| abstract_inverted_index.(95% | 217, 225 |
| abstract_inverted_index.(IQR | 165 |
| abstract_inverted_index.(OS) | 84 |
| abstract_inverted_index.2015 | 106 |
| abstract_inverted_index.ADT, | 196 |
| abstract_inverted_index.Data | 126 |
| abstract_inverted_index.data | 55, 111 |
| abstract_inverted_index.have | 35, 270 |
| abstract_inverted_index.high | 232, 261, 265 |
| abstract_inverted_index.late | 291 |
| abstract_inverted_index.mPCa | 90, 256 |
| abstract_inverted_index.many | 65 |
| abstract_inverted_index.most | 7 |
| abstract_inverted_index.novo | 89, 255 |
| abstract_inverted_index.over | 155 |
| abstract_inverted_index.part | 22 |
| abstract_inverted_index.poor | 249 |
| abstract_inverted_index.this | 72, 301 |
| abstract_inverted_index.were | 124, 138, 153, 174, 246 |
| abstract_inverted_index.with | 29, 42, 59, 87, 114, 253, 260, 275 |
| abstract_inverted_index.year | 214 |
| abstract_inverted_index.<6 | 242 |
| abstract_inverted_index.(ADT) | 49 |
| abstract_inverted_index.2019, | 108 |
| abstract_inverted_index.45.2% | 224 |
| abstract_inverted_index.92.4% | 216 |
| abstract_inverted_index.Among | 27 |
| abstract_inverted_index.among | 10, 16, 56 |
| abstract_inverted_index.grade | 188 |
| abstract_inverted_index.least | 205 |
| abstract_inverted_index.lower | 170 |
| abstract_inverted_index.shown | 36 |
| abstract_inverted_index.study | 73, 102, 158 |
| abstract_inverted_index.total | 149 |
| abstract_inverted_index.tract | 172 |
| abstract_inverted_index.(UCI). | 97 |
| abstract_inverted_index.5-year | 81, 157, 272 |
| abstract_inverted_index.Cancer | 95 |
| abstract_inverted_index.Uganda | 94, 258 |
| abstract_inverted_index.cancer | 3, 9, 32, 118 |
| abstract_inverted_index.cohort | 101 |
| abstract_inverted_index.common | 8 |
| abstract_inverted_index.cycles | 207, 243 |
| abstract_inverted_index.grades | 263 |
| abstract_inverted_index.levels | 268 |
| abstract_inverted_index.median | 161 |
| abstract_inverted_index.n=211) | 202 |
| abstract_inverted_index.nearly | 177 |
| abstract_inverted_index.reduce | 290 |
| abstract_inverted_index.scarce | 63 |
| abstract_inverted_index.score, | 234 |
| abstract_inverted_index.second | 6 |
| abstract_inverted_index.years. | 167, 230 |
| abstract_inverted_index.(70.3%, | 201 |
| abstract_inverted_index.(96.7%, | 180 |
| abstract_inverted_index.(RLSs). | 68 |
| abstract_inverted_index.(mPCa), | 33 |
| abstract_inverted_index.(n=120) | 184 |
| abstract_inverted_index.Gleason | 233 |
| abstract_inverted_index.Overall | 210 |
| abstract_inverted_index.between | 105 |
| abstract_inverted_index.highest | 15 |
| abstract_inverted_index.n=290), | 181 |
| abstract_inverted_index.outcome | 54 |
| abstract_inverted_index.overall | 40, 82, 132, 273 |
| abstract_inverted_index.period. | 159 |
| abstract_inverted_index.present | 259 |
| abstract_inverted_index.scores. | 191 |
| abstract_inverted_index.studies | 34, 295 |
| abstract_inverted_index.therapy | 48, 61 |
| abstract_inverted_index.treated | 58, 91 |
| abstract_inverted_index.urinary | 171 |
| abstract_inverted_index.61.5-74) | 166 |
| abstract_inverted_index.</bold>A | 148 |
| abstract_inverted_index.However, | 53 |
| abstract_inverted_index.Patients | 252 |
| abstract_inverted_index.Prostate | 2 |
| abstract_inverted_index.addition | 193 |
| abstract_inverted_index.androgen | 46 |
| abstract_inverted_index.baseline | 266 |
| abstract_inverted_index.clinical | 78, 128 |
| abstract_inverted_index.declined | 222 |
| abstract_inverted_index.disease. | 26 |
| abstract_inverted_index.efficacy | 299 |
| abstract_inverted_index.enrolled | 154 |
| abstract_inverted_index.evaluate | 297 |
| abstract_inverted_index.evidence | 121 |
| abstract_inverted_index.improved | 271 |
| abstract_inverted_index.indicate | 144 |
| abstract_inverted_index.majority | 198 |
| abstract_inverted_index.patients | 17, 28, 57, 86, 113, 152, 179, 186, 200 |
| abstract_inverted_index.presence | 236 |
| abstract_inverted_index.prostate | 31, 117 |
| abstract_inverted_index.received | 203 |
| abstract_inverted_index.reported | 175 |
| abstract_inverted_index.settings | 67 |
| abstract_inverted_index.survival | 41, 83, 137, 211, 274 |
| abstract_inverted_index.symptoms | 173 |
| abstract_inverted_index.visceral | 238 |
| abstract_inverted_index.Institute | 96 |
| abstract_inverted_index.Mortality | 13 |
| abstract_inverted_index.P<0.05 | 140 |
| abstract_inverted_index.conducted | 104 |
| abstract_inverted_index.confirmed | 116 |
| abstract_inverted_index.determine | 76 |
| abstract_inverted_index.outcomes. | 250 |
| abstract_inverted_index.receiving | 195, 241 |
| abstract_inverted_index.recommend | 287 |
| abstract_inverted_index.reviewed. | 125 |
| abstract_inverted_index.settings, | 20 |
| abstract_inverted_index.survival, | 133 |
| abstract_inverted_index.treatment | 298 |
| abstract_inverted_index.considered | 142 |
| abstract_inverted_index.extracted. | 139 |
| abstract_inverted_index.first-line | 284 |
| abstract_inverted_index.histologic | 262 |
| abstract_inverted_index.laboratory | 130 |
| abstract_inverted_index.late-stage | 25 |
| abstract_inverted_index.metastasis | 123, 239 |
| abstract_inverted_index.metastatic | 30 |
| abstract_inverted_index.predictors | 135, 247 |
| abstract_inverted_index.treatment. | 285 |
| abstract_inverted_index.worldwide. | 12 |
| abstract_inverted_index.combination | 277 |
| abstract_inverted_index.deprivation | 47 |
| abstract_inverted_index.improvement | 38 |
| abstract_inverted_index.population. | 302 |
| abstract_inverted_index.prospective | 294 |
| abstract_inverted_index.significant | 37 |
| abstract_inverted_index.statistical | 145 |
| abstract_inverted_index.36.8%-53.2%) | 227 |
| abstract_inverted_index.chemotherapy | 245, 279 |
| abstract_inverted_index.histological | 190 |
| abstract_inverted_index.presentation | 292 |
| abstract_inverted_index.radiological | 120 |
| abstract_inverted_index.taxane-based | 51 |
| abstract_inverted_index.88.6%-94.9%), | 219 |
| abstract_inverted_index.chemotherapy. | 52, 209 |
| abstract_inverted_index.interventions | 288 |
| abstract_inverted_index.presentation, | 169 |
| abstract_inverted_index.retrospective | 100 |
| abstract_inverted_index.significance. | 146 |
| abstract_inverted_index.<bold>Results: | 147 |
| abstract_inverted_index.histologically | 115 |
| abstract_inverted_index.characteristics | 79 |
| abstract_inverted_index.chemo-endocrine | 60 |
| abstract_inverted_index.characteristics, | 131 |
| abstract_inverted_index.resource-limited | 19, 66 |
| abstract_inverted_index.<bold>Methods:</bold> | 98 |
| abstract_inverted_index.<title>Abstract</title> | 0 |
| abstract_inverted_index.<bold>Background:</bold> | 1 |
| abstract_inverted_index.<bold>Conclusion</bold>: | 251 |
| cited_by_percentile_year | |
| countries_distinct_count | 3 |
| institutions_distinct_count | 7 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/1 |
| sustainable_development_goals[0].score | 0.6000000238418579 |
| sustainable_development_goals[0].display_name | No poverty |
| citation_normalized_percentile.value | 0.37097126 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |